Sarcomas (SR Patel, Section Editor)

Current Oncology Reports

, Volume 15, Issue 4, pp 347-355

First online:

Vascular Sarcomas

  • Vinod RaviAffiliated withSarcoma Medical Oncology, University of Texas MD Anderson Cancer Center Email author 
  • , Shreyaskumar PatelAffiliated withSarcoma Medical Oncology, University of Texas MD Anderson Cancer Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Vascular sarcomas are soft-tissue tumors that arise from the endothelium with a malignant potential. This review discusses the management of epithelioid hemangioendothelioma (EHE) and angiosarcoma. EHE is a vascular tumor of intermediate malignant potential with an indolent course. EHE arising from the liver, lung, or bone tends to be multifocal and the rate of progression is slow and often unpredictable. Treatment should be considered in patients with significant symptomatic deterioration and/or progressive disease on imaging studies. Various cytotoxic and targeted therapies are available for management, with disease stabilization as the most common outcome. Angiosarcoma is an aggressive vascular tumor with a high malignant potential. Multidisciplinary care is critical for the management of localized disease, and the best outcomes are often observed in patients when a combination of systemic and local therapy options is used. Metastatic angiosarcoma is treated primarily with systemic therapy, and several cytotoxic and targeted therapies are available, alone or in combination. The choice of therapy depends on several factors, such as cutaneous location of the tumor, performance status of the patient, toxicity of the treatment, and patient goals.


Epithelioid hemangioendothelioma Angiosarcoma Vascular tumors Vascular sarcomas Vascular sarcoma Angiosarcoma treatment Bevacizumab Sorafenib Sunitinib Orally administered cyclophosphamide Pazopanib Paclitaxel Gemcitabine Docetaxel Adriamycin Doxorubicin Ifosfamide